Submitted protocols are reviewed by both the Clinical Protocol Review Committee (LSU SVM Department of Veterinary Clinical Sciences) and LSU’s Institutional Animal and Care Use Committee (IACUC) with the intent to ensure that welfare and confidentiality matters are observed. These reviews are patterned on “Good Clinical Practices” for conduct of clinical trials in human medicine. For further information on GCP, please see http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm.
For Faculty and Staff:
The Clinical Trials Protocol can be downloaded here. It is only accessible by faculty and staff. You will need to enter your PAWS ID and password. Type your PAWS ID with "LSU\" preceding it (e.g., LSU\mtiger).
Title of Clinical Trial | Species | Investigator |
Canine Osteosarcoma Study
Eligible dogs must have been diagnosed with osterosarcoma by either cytologically or histologically. Patients with local, regional, or systemic metastatic disease are eligible for treatment. Patients with an anticipated survival time without treatment of more than 2 months are required.
In this study, dogs diagnosed with osteosarcoma are invited to participate. The participant patient will be treated with amputation, IL-12 and standard chemotherapy treatment. IL-12 administration via electroporation will be performed 2-7 days prior to and 2-7 days post surgery. If you are not satisfied with the outcome, you can withdraw your pet from the clinical trial anytime. The participant patients will be anesthetized through LSU-SVM anesthesia service for performing the treatment, including injection of the immune stimulator via electroporation. Needles will be inserted into tumors for injection and electroporation. The electroporation lasts for less than one second and the whole procedure last for less than 5 minutes once dogs are under anesthesia. A total of two IL-12 administrations via electroporation will be performed. Prior to both the first and the second IL-12 administration, blood will be drawn for CBC, serum chemistry profile, and cytokine profile analysis. A follow-up check will be performed one week after the second treatment. Carbplatin (a standard chemotherapy drug) will be administered every 3 weeks, and a total of five doses will be administered. A follow-up recheck will be performed every other month after completion of the chemotherapy protocol. | canine | Dr Shulin Li |
| Establishment of a technique for transesophageal echocardiogram in birds | avian | Dr Tom Tully |
| Contrast harmonic ultrasound imaging of the normal pancreas and pancreatitis in dogs | canine | Dr Lorrie Gaschen |
| Altered intercellular communication, arrhythmias, and sudden death in Boxer dogs | canine | Dr Romain Pariaut |
| IL12 gene therapy for enhancing therapeutic efficacy of bleomycin against oral tumors in owners’ dogs | canine | Dr Shulin Li |
| Contrast harmonic and spectral Doppler ultrasound imaging of visceral lymph nodes in dogs | canine | Dr Lorrie Gaschen |
| Use of contrast-enhanced harmonic ultrasound for differentiating benign versus malignant liver nodules in dogs | canine | Dr Lorrie Gaschen |
| Characterization of CSF lactate concentrations in dogs evaluated for neurologic disease | canine | Dr Isabelle Cattin |
| Characterization of plasma matrix metalloproteinase-2 and -9 activities in dogs with naturally occurring mitral valve disease | canine | Dr Romain Pariaut |
| Mitoxantrone vs. Mitoxantrone + DTIC for dogs with refractory lymphoma | canine | Dr Tracy Gieger |
Comet-tail artifacts in normal dogs and dogs with cardiogenic pulmonary edema | canine | |
| Comparison of passive range of motion achieved by owners instructed with different teaching modalities versus trained veterinary personnel | canine | Dr Erica Hartmann |
| Comparison of ultrasound biometry and automatic keratometry for determination of corneal curvature in dogs | canine | |
| An evaluation of the clinical efficacy of pergolide mesylate tablets for the control of clinical signs associated with pituitary pars intermedia dysfunction (equine Cushing’s disease) in horses | equine | Dr Frank Andrews |
| Development of 2D-PAGE protein maps for healthy and chronic renal failure cats | feline | Dr Mark Acierno |
| Use of contrast harmonic ultrasound imaging for the diagnosis and differentiation of pancreatic diseases in cats | feline | Dr Nathalie Radamacher |
| Role of acute phase proteins in feline chronic kidney disease | feline | Dr Mark Acierno |
| Use of HMG CoA reductase inhibitors for the treatment of chronic kidney disease in dogs | feline | Dr Mark Acierno |
Saving Lives, Finding Cures, Changing Lives Every Day